about
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cellsSynthetic and Biological Studies of Sesquiterpene Polygodial: Activity of 9-Epipolygodial against Drug-Resistant Cancer CellsA potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitorCarboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance.Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancerPIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cellsAdvancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary aminesPIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.Jonquailine, a new pretazettine-type alkaloid isolated from Narcissus jonquilla quail, with activity against drug-resistant cancer.Novel approaches to glioma drug design and drug screening.Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization.A good molecular target for prostate cancer chemotherapy.Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells.A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.d -Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis.5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cellsApoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
P2860
Q24649780-EFC2C41C-7697-4FE2-A5F1-36EC04EE2808Q27335770-F2930650-B1A0-494C-8B13-54D270DA4A7FQ28541630-4060D70C-959A-4DC2-A453-3E34CCC371E6Q28834689-AD7D84A1-F357-481D-BAEB-22D9A4911272Q33812795-B8CEC55E-957F-4FC4-AFD3-0B6830AD1550Q34005719-E1B3C3FA-6F66-491C-A81A-0DF6688C3C0AQ34418413-448B469E-3457-4D60-8E9F-3A4FF7DAFF52Q35068026-6C31BF92-312E-42F8-8007-82E29B75D4CEQ35975007-B0C3BE1E-0CDC-40D5-B3A2-ECAB45FF07B9Q36198988-6C55D1B0-0019-462D-A50D-62214DA97EF7Q36896806-6E634267-9A59-477B-8439-86C2A5F9E9E5Q37088195-1FE09630-CE01-4BE1-A170-97565D0E136AQ38112184-BAA7AC8F-014D-4892-B204-94A25451382AQ39316544-6958CB7D-5360-4EAB-A481-A32DF249183BQ39503640-E5FA3CC5-0B20-4363-A7AF-6A1D6109B8A9Q39593019-927E78D1-9CE4-476B-BC2B-F8C7595A8753Q39777250-FA6CDC51-8857-4179-9298-BACA0A56A0DFQ39940476-022CBCD6-39E9-47E5-A887-D5A4BA553AF4Q40284731-1ECD5AEF-158F-4CA4-884C-89DD67D18FB8Q40351640-F0D9648E-16EF-4713-84B1-392D3AC74FB5Q40470308-8F1CD2B9-2E2D-4BDD-82CB-5CCC4F913F94Q41292697-32023B29-7EB6-4F50-B2B0-44DE53F0D36AQ41744145-71B28576-409B-4A20-A579-21C29CCF6C46Q42751429-31DC13D7-7708-456E-B47D-A702F61FC0D4Q46033872-9D5F215D-632B-452B-A540-D4B9ED7EB88AQ54537291-F247477A-1FD8-4EC1-A6D8-F27D81276D48
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Overcoming multidrug resistance in taxane chemotherapy.
@ast
Overcoming multidrug resistance in taxane chemotherapy.
@en
Overcoming multidrug resistance in taxane chemotherapy.
@nl
type
label
Overcoming multidrug resistance in taxane chemotherapy.
@ast
Overcoming multidrug resistance in taxane chemotherapy.
@en
Overcoming multidrug resistance in taxane chemotherapy.
@nl
prefLabel
Overcoming multidrug resistance in taxane chemotherapy.
@ast
Overcoming multidrug resistance in taxane chemotherapy.
@en
Overcoming multidrug resistance in taxane chemotherapy.
@nl
P2093
P2860
P356
P1476
Overcoming multidrug resistance in taxane chemotherapy.
@en
P2093
Iwao Ojima
Raphaël Geney
loana Maria Ungureanu
P2860
P304
P356
10.1515/CCLM.2002.161
P577
2002-09-01T00:00:00Z